Clearstead Trust, LLC Exelixis, Inc. Transaction History
Clearstead Trust, LLC
- $473 Million
- Q2 2025
A detailed history of Clearstead Trust, LLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Clearstead Trust, LLC holds 128 shares of EXEL stock, worth $5,292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
128
Previous 77
66.23%
Holding current value
$5,292
Previous $2,000
150.0%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding EXEL
# of Institutions
688Shares Held
260MCall Options Held
1.41MPut Options Held
1.55M-
Black Rock Inc. New York, NY33.5MShares$1.39 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA27.5MShares$1.14 Billion0.02% of portfolio
-
Farallon Capital Management LLC San Francisco, CA16MShares$663 Million3.18% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.8MShares$654 Million0.99% of portfolio
-
State Street Corp Boston, MA11.4MShares$471 Million0.02% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $13.3B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...